Glenmede Trust’s Bicycle Therapeutics BCYC Stock Holding History

Glenmede Trust’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,436	Closed	-$267K	–	1329
2021 Q3	$267K	Sell	6,436 -3,058	-32%	-$107K	﹤0.01%	1057
2021 Q2	$288K	Sell	9,494 -414	-4%	-$12.5K	﹤0.01%	1042
2021 Q1	$295K	Buy	+9,908	New	+$256K	﹤0.01%	976

Other funds holding BCYC

RCI

Ridgeback Capital Investments Miami Beach, Florida $560K AUM

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Glenmede Trust's BCYC Position: Q4 2021 in Review

Glenmede Trust sold out of Bicycle Therapeutics (BCYC) in Q4 2021, closing a stake of 6,436 shares — an estimated $267K sold.

Glenmede Trust first reported a position in BCYC in Q1 2021 and held it in 3 quarters. The position peaked at $295K in Q1 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2021.

Glenmede Trust reported no remaining Bicycle Therapeutics position as of Q4 2021 after selling out during the quarter.
Glenmede Trust sold 6,436 Bicycle Therapeutics shares in Q4 2021, an estimated $267K.
Glenmede Trust first reported a position in Bicycle Therapeutics in Q1 2021 and held it in 3 quarters.
Glenmede Trust's Bicycle Therapeutics position peaked at $295K in Q1 2021.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2021.

Based on Glenmede Trust's 13F filing for Q4 2021, filed 15 Feb 2022.